ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 6 for:    17008531 [PUBMED-IDS]

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01858662
Recruitment Status : Terminated (due to poor recrutment)
First Posted : May 21, 2013
Last Update Posted : April 15, 2016
Sponsor:
Collaborator:
Grand Hôpital de Charleroi
Information provided by (Responsible Party):
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Brief Summary:
To analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with cetuximab combined with FOLFOX or FOLFIRI regimen in a prospective cohort (RAS and B-RAF WT tumors) and to correlate this response with patient's outcome.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Procedure: Metastases Resection ( multiple steep surgery possible) Drug: 5-Fluorouracile Drug: leucovorin L Drug: Oxaliplatin Drug: Irinotecan Drug: Cetuximab Phase 2

Detailed Description:

This is a phase II , openlabel, randomized study in patients with confirmed diagnosis of potentially or borderline resectable metastatic colorectal adenocarcinoma (RAS and B-RAF WT tumors ), who have not received prior chemotherapy for their metastatic disease.

The study is designed to compare pathological responses observed after pre-operative chemotherapy cetuximab with FOLFOX or FOLFIRI.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 4 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
Study Start Date : January 2014
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab

Arm Intervention/treatment
Active Comparator: oxaliplatin +leucovorin L+5FU+ cetuximab
oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
Procedure: Metastases Resection ( multiple steep surgery possible)
Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.

Drug: 5-Fluorouracile
5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
Other Name: 5FU

Drug: leucovorin L
Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
Other Names:
  • elvorine
  • isovorin

Drug: Oxaliplatin
Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
Other Name: Eloxatin

Drug: Cetuximab
Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
Other Name: erbitux

Active Comparator: Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab
Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
Procedure: Metastases Resection ( multiple steep surgery possible)
Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.

Drug: 5-Fluorouracile
5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
Other Name: 5FU

Drug: leucovorin L
Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
Other Names:
  • elvorine
  • isovorin

Drug: Irinotecan
Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
Other Names:
  • Campto
  • Irinosin

Drug: Cetuximab
Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
Other Name: erbitux




Primary Outcome Measures :
  1. Major Pathological Response Rate [ Time Frame: Average 3 months (after resection of metastases) ]
    Major pathological response rate (MPRR) is defined as the proportion of patients presenting a major pathological response. Pathologic response will be evaluated according the Rubbia-Brandt Tumor Regression Grade classification .For patients with multiple colorectal metastases the global pathological response will be categorized based on the mean TRG of all metastases.: a major response is defined as a mean TRG < 3, a partial response is defined for patient presenting a mean TRG ≥3 and <4, and a no response for patient with a mean TRG ≥4.


Secondary Outcome Measures :
  1. progression free survival [ Time Frame: at 6 months and at 12 months after randomization ]
    -Progression Free Survival (PFS) is defined as the time from randomization to the time of first event (relapse of the original mCRC, development of a new colorectal cancer or death due to any cause). Patients without any such event at the time of data analysis will be censored at the last date they were known to be event-free. PFS analysis will be based on tumour assessments and survival follow-up assessments.

  2. Overall survival [ Time Frame: At the end of the study ]
    The overall survival will be analyzed at the end of study (3 year of recruitment and one year of follow-up).

  3. Clinical response rate [ Time Frame: at time of surgery - ]
    Clinical response rate at time of surgery: Clinical tumour response will be measured according to the RECIST 1.1 criteria

  4. Metabolic response rate [ Time Frame: At time of surgery - average 3 months ]
    Metabolic response rate at time of surgery (in selected centres only, optional): Metabolic tumour response will be measured according to the EORTC criteria . PET-Scan evaluation remains optional to selected centres only.

  5. post operative complications [ Time Frame: one month after surgery ]

    . Severe pre- or postoperative complications within 30 days of surgery:

    • surgery-associated bleeding requiring replacement with > 4 units of erythrocyte concentrates,
    • wound infection,
    • intra-abdominal infection,
    • severe sepsis (American College of Chest physicians/Society of Critical Care Medicine, 1992),
    • impaired wound healing,
    • subphrenic or perihepatic abscess requiring drainage during hospital stay or within 30 days after the operation,
    • re-laparotomy connected with the resection,
    • a biliary fistula for more than 10 days with a discharge of > 100 mL/day,
    • transient liver failure (bilirubin > 10 mg/dL lasting > 3 days),
    • renal failure requiring dialysis,
    • respiratory failure with renewed necessary mechanical ventilation, venous thromboembolism,
    • cardiac failure,
    • death of the patient as a result of the operation.

  6. Curative resection rate [ Time Frame: At time of surgery ]
    Curative resection rate (R0 resection) is defined by the surgical clearance (+/- radiofrequency ablation) of all detectable hepatic lesions with tumor-free margins at histo-pathological evaluation.

  7. Chemotherapy-associated hepatotoxicity: [ Time Frame: at time of surgery ]
    Systemic neo-adjuvant chemotherapy in mCRC frequently causes morphological lesions involving hepatic microvasculature . Sinusoidal obstruction, complicated by perisinusoidal fibrosis and veno-occlusive lesion of the non tumoral liver, should be included in the list of the adverse side-effects of colorectal systemic chemotherapy, in particular related to the use of oxaliplatin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Female or male patients with at least 18 years at the time the informed consent is signed
  2. ECOG performance status 0 or 1
  3. Histological or cytological confirmed diagnostic of adenocarcinoma of the colon or rectum, with or without primary tumour in situ. Wild-type RAS and B-RAF tumor status.
  4. Patients with potentially resectable metastatic disease at diagnosis and for whom a chemotherapy first in a curative intent is recommended . Resectability could be planed in one or multiple stage if indicated. As commonly admitted, resectability means the surgical clearance (+/- radiofrequency ablation) of all detectable (liver) lesions with tumor-free margins and compatible with an adequate hepatic reserve. Practically, bilateral tumor location, number and location of lesions, and inadequate hepatic reserve remain the main decisional factors.
  5. Partial and minor resection of metastatic disease is allowed within 3 months before inclusion if patient has never received chemotherapy for mCRC.
  6. Extra hepatic metastatic location is limited to 1 site.
  7. Patients may have received adjuvant chemotherapy or (neo-) adjuvant chemo-radiotherapy to the pelvis, provided the last dose of chemotherapy was administered at least 6 months prior to inclusion (12 months for oxaliplatin). Previous radiotherapy to the pelvis is not an exclusion criterion.
  8. Adequate haematological, renal and hepatic function as follows:

    Haematological:

    haemoglobin >9g/dl Neutrophils > 1.5 x 109/L Platelets > 100 x 109/L

    Renal:

    Creatinine< 1.5 x ULN (Upper Limit of Normal)

    Hepatic:

    Bilirubin < or equal 1.5 X ULN AST (Aspartate Aminotransferase),and ALT (Alanine Aminotransferase)< or equal 5 x ULN, Phos Alc< or equal 5 x ULN

  9. Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active using an acceptable method of contraception.
  10. Male patients must be surgically sterile or if sexually active and having a pre-menopausal partner must be using an acceptable method of contraception.
  11. Life expectancy of at least 3 months without any active treatment.

Exclusion Criteria:

  • 1.Definitively non resectable mCRC at diagnosis
  • 2.Prior chemotherapy or systemic therapy for mCRC. Adjuvant chemotherapy for colorectal cancer is not an exclusion criterion provided that it was completed more than 6 months prior to inclusion. Oxaliplatin-based chemotherapy must be completed more than 1 year prior to inclusion.
  • 3.Prior utilization of cetuximab, panitumumab (or other anti-EGFR (epidermal growth factor receptor)therapy).
  • 4.Previous radiotherapy delivered to the upper abdomen.
  • 5 Non mesurable disease( RECIST 1.1 criteria)
  • 6.Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or thrombosis as determined by clinical or radiologic assessment.
  • 7.Prior major liver resection: remnant liver < 50% of the initial liver volume.
  • 8.Non-malignant disease that would render the patient unsuitable for treatment according to this protocol.
  • 9.Concurrent central nervous systems metastases
  • 10.Peripheric neuropathy ≥ grade 2.
  • 11.Interstitial lung disease
  • 12.Pregnant or breast feeding.
  • 13.The patient has previous or concomitant malignancies, except: Invasive malignancies in remission for more than 5 years and non melanoma skin cancer or carcinoma in situ of the cervix.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01858662


Locations
Belgium
Grand Hôpital de Charleroi
Charleroi, Hainaut, Belgium, 6000
clinique Saint Luc
Bouge, Belgium, 5004
Cliniques universitaires Saint-Luc - UCL
Brussels, Belgium, 1200
Centre Hospitalier Jolimont Lobbes
La Louvière, Belgium, 7100
CHU liège (Sart Timan)
Liège, Belgium, 4000
Clinique Saint Pierre Ottignies
Ottignies, Belgium, 1340
CHU-UCL Dinant-Godinne
Yvoir, Belgium, 5530
Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Grand Hôpital de Charleroi
Investigators
Principal Investigator: Marc Van den Eynde, MD Cliniques universitaires Saint-Luc - UCL
Principal Investigator: Javier Carrasco, MD PhD Grand Hôpital de Charleroi

Publications:

Responsible Party: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
ClinicalTrials.gov Identifier: NCT01858662     History of Changes
Other Study ID Numbers: CET-ONCO2012
2012-005249-19 ( EudraCT Number )
First Posted: May 21, 2013    Key Record Dates
Last Update Posted: April 15, 2016
Last Verified: April 2016

Keywords provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:
metastatic colorectal cancer
Liver
cetuximab
Pathological response

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Oxaliplatin
Irinotecan
Camptothecin
Cetuximab
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action